COVID-19 has brought new challenges to primary care, especially for vulnerable populations like the elderly and the chronically ill. Now, more than ever, there is a growing need for smart solutions in order to reduce infections, increase cost-effectiveness and decrease time.
Sanolla’s enabling technology offers a unique proposition in assessing for COVID-19 which cannot be detected using mainstream stethoscopes. Recent studies demonstrate that COVID-19 patients present “silent hypoxemia” that might be a projection of ‘silent pneumonia’. Our products have the ability to identify and classify the full lung sound spectrum, including the infrasound range (inaccessible until now). The assessment is immediate, accurate and provides Ad-Hock answers.
|Recently, Sanolla led a consortium comprised of seven European entities and companies. Sanolla and its partners were granted a total of €5 million funding for the PyXy.AI project, under the Horizon 2020 program (a program designed to fight COVID-19). Achieving a perfect score of 15 out of 15, given by all the examiners, Sanolla’s proposal earned outstanding commendations.|
In a multi-center clinical trial, the company has collected 3,290 lung- sound files from 217 COVID-19 patients and 2,016 lung sound files from 144 healthy subjects. These files were sampled with the intent to develop an AI-powered classifier for COVID-19. Illustrated below, we present the preliminary results (using data collected up until Jan 12, 2021) to demonstrate the accuracy of our AI algorithms in detecting COVID-19. These results underscore how our technology will enhance the speed and accuracy of COVID-19 assessment.
|Sanolla has entered an extensive clinical trial conducted all across Israel. Trial kick off was in the presence of Mr. Yoav Kish (Israeli Deputy Health Minister). In recent news segment on Israeli 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 𝟏𝟐 𝐧𝐞𝐰𝐬, our unique infrasound technology for fighting COVID-19 was broadcasted.|
Immediate primary care diagnosis has never been this vital. Sanolla's breakthrough smart diagnostic solutions for physicians and patients can support the early assessment and monitoring of cardiopulmonary conditions such as congestive heart failure, pneumonia, asthma, chronic obstructive pulmonary disease (COPD), COVID-19 and more.
Based on AI-powered detection and analysis of previously inaccessible body infrasound and other important vital signs (ECG, heart rate, oxygen level, body temperature and respiratory cycle), Sanolla’s products can provide immediate and accurate assessment for everyone, everywhere; reducing in-clinic visits, saving time and money, and lowering the associated risk of exposure to infections.
VoqX detects infrasound and audible sounds, identifies clinical condition based on our AI algorithms and displays diagnosis through our proprietary sound signature image. This can reduce the need for CT or X-Ray radiation or invasive blood tests and provides health care professionals a precise, fast diagnosis as well as:
An intuitive self assessment and monitoring device, the PyXy provides patients with a piece of mind and a positive life impact from the comfort of their own home, by providing indication of the clinical condition on the device display based on AI technology. Ideally suited for:
SonoX, a revolutionary tool in chest functionality estimation, captures complete chest sounds including infrasound spectrum and uses deep learning classification to detect clinical abnormalities. SonoX maps sound sources to a physical 3D lung simulator highlighting irregularities:
You are welcome to see this short video where Sanolla’s CEO, Dr. Doron Adler presents the company and the products:
Press HERE to watch the movie.
Heart and Lung Auscultation
Founded in 2016 by a team of visionary industry experts with a mission of enhancing primary care, for health care professionals and patients, Sanolla leads the world’s first AI based infrasound auscultation technology. Capturing and analyzing the body's full spectrum of sounds providing critical medical data at reduced costs while notably improving patients’ lives. The company has 3 product lines with promising clinical results, is ISO 13485 certified, with several technology patents and it operates in the multibillion-dollar primary care diagnostic devices market.
Chief Medical Officer
Prof. Banai is one of Israel’s leading Cardiologists and a well-known researcher. Professor Banai leads a productive and busy career as both the Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Souraski Medical Center, Tel Aviv, Israel and as the Medical Director for Neovasc Inc.
He is a full academic Professor of Cardiology at the Tel Aviv University, Sackler School of Medicine. Head, of the Nicholas and Elizabeth Slezak Super Center for Cardiac Research and Biomedical Engineering, and the Walton Chair of Interventional Cardiology at the Tel Aviv University.
Professor Banai is the author of more than 200 peer-reviewed papers and book chapters and has participated in many clinical and pre-clinical research.
Chairman, Founder & CEO
Dr. Adler is a serial entrepreneur with an impressive track record in establishing successful med-tech companies.
Prior to founding Sanolla, Dr. Adler was the founder and CEO of Cbyond for 15 years until it was acquired by Olympus for $2.1B. During this time he transitioned into the role of CEO of Olympus Israel and CTO for Olympus Surgical US.
Dr. Adler began his start-up career as the founder of iSight and was also part of the founding team and VP R&D of Given Imaging, later acquired by Covidien for $860M.
After his military service as a major in the Israeli Air Force he worked at Elbit – a leading global high-tech company.
Dr. Adler holds a Ph.D., M.Sc. and B.Sc. degrees in Electrical Engineering all from Technion – the Israel Institute of Technology. He has filed more than 130 patents, with most of these patents implemented in existing products.
Co-Founder & COO
David is an experienced manager specializing in all aspects of operational excellence.
Prior to co-founding Sanolla, David was Director of Operations for Olympus Medical which acquired CByond where he held the role of COO. Previously, he spent 14 years in various management roles within A.R. Telcom system.
David worked for 12 years with the Israeli Ministry of defense forces and holds a B.A. from Haifa University and an MBA from Bar-Ilan University in Israel.
Chief Business Development Officer
David is entrepreneur, inventor and medical device industry executive for past 20 years, having in-depth experience in managing and creating value for medical device companies. Specialized in developing and introducing a wide range of medical technologies to market, strategic planning, strategic collaborating and M&A’s.
In 2009 David established Stimatix GI and serves as its CEO. In 2014, Stimatix assets were acquired by B.Braun. Prior to Stimatix David served as V.P. of R&D Vision Sciences Inc., a N.Y. based medical device company specializing in flexible endoscopy. Prior to Vision Sciences Inc. he served as COO and R&D leader at CByond (Olympus-Gyrus-ACMI subsidiary) specializing in minimal invasive surgery.
To date, David published more that 30 patents applications of which 18 been granted.
David holds an MBA from Haifa University and a B.Sc. electrical engineering from Ben-Gurion University of the Negev (honors).
Prof. Yochai Adir is director of the Lung Institute at the Carmel medical center, director of Haifa area of Clalit Health Services (HMO) and chairman of the Israeli Association of Pulmonary Diseases. He specializes in pulmonary hypertension, non-invasive respiration, bronchiactomy, CF in adults, interstitial lung disease and in addition, advanced invasive bronchoscopy. Prof. Adir is a medical graduate of the Technion– Israel Institute of Technology, and in his last military position he was commander of the Marine Medicine Institute of the Navy and was discharged with the rank of Lieutenant Colonel.
Prof. Karkabi is a board-certified physician in family medicine and a clinical associate professor in family medicine at the Technion– Israel Institute of Technology. He has been practicing family medicine in Israel for more than 40 years and combines practice with academic activities. He functioned as the director of the French Carmel community clinic in Clalit Health Services, Chairman of the Department of Family Medicine, Clalit Health Services, Haifa and Western Galilee District for 14 years, Chairman of the Division of Family Medicine, Rappaport Faculty of Medicine, Technion, and Chairman of the Professional Committee in Family Medicine, the Scientific Council of IMA. Prof. Karkabi has a Master in Medical Humanities and has published more than 50 publications in Medical Humanities and other topics in family medicine.
Prof. Avinoam Shiran has been the Director of the Echocardiography Unit at Lady Davis Carmel Medical Center since 2006. He has a specialty in Internal Medicine from Bnai-Zion Medical Center and in Cardiology from Carmel Medical Center.
He studied acupuncture and ultrasound of blood vessels at Washington DC Medical Center, USA. Prof. Shiran was Chairman of the Department of Echocardiography of the Israel Cardiology Association from 2005-2007.
Israel Cohen is a Professor of electrical engineering at the Technion– Israel Institute of Technology. He is also a visiting professor at Northwestern Polytechnical University, Xi’an, China. His areas of interest include analysis and modeling of acoustic signals, statistical signal processing, source localization, microphone arrays, system identification, image analysis and processing and deep learning. He is a co-editor of the Multichannel Speech Processing Section of the Springer Handbook of Speech Processing and a coauthor of Fundamentals of Signal Enhancement and Array Signal Processing. He is an IEEE Fellow “for contributions to the theory and application of speech enhancement”, and Distinguished Lecturer of the IEEE Signal Processing Society (2019-2020).